Suppr超能文献

在接受干扰素治疗患者的长期随访过程中,更具致病性的丙型肝炎病毒基因II型的选择。

Selection of more pathogenic hepatitis C virus genotype II during long-term follow-up of interferon-treated patients.

作者信息

Villa E, Buttafoco P, Merighi A, Grottola A, Ferretti I, Ferrari A, Callea F, Trande P, Rebecchi A M, Manenti F

机构信息

Chair of Gastroenterology, University of Modena, Italy.

出版信息

J Mol Med (Berl). 1995 May;73(5):249-54. doi: 10.1007/BF00189925.

Abstract

The behavior of hepatitis C virus (HCV) infection with regards to type and number of HCV genotypes (tested with genotype-specific nested polymerase chain reaction) was evaluated in 60 patients with anti-HCV-positive chronic active hepatitis without cirrhosis [17 untreated and 43 subjects undergoing single or repeat courses of interferon (IFN) therapy] during a mean follow-up period of 76 +/- 18 months. In untreated patients (2 genotype I, 6 genotype II, 9 mixed infections) 4 out of 9 mixed infections selected for genotype II at the end of follow-up. Of the 43 treated patients 10 were long-term responders with histological remission, 6 were short-term responders, and 22 did not respond. Fifteen of the latter patients received another course of IFN therapy, and only 3 patients responded. Eight of the 10 responders had infection with a single genotype (4 gt I, 3 gt II, 3 gt III). After IFN therapy, all but 2 patients cleared the HCV infection. The responders to the second IFN course (1 gt I, 1 gt II, 1 gt III) remained viremic. Of the short-term responders, 2/6 patients had genotype II and 4 had a mixed infection (3 gt II +/- I and 1 gt II +/- III); gt III became prevalent in the latter in all but one patient. Of the nonresponders 18/24 had more than one genotype, 5 were genotype II at baseline and one had genotype I. At the end of the follow-up period 15/18 with mixed infection had selected for gt II (P < 0.01 vs. untreated patient).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在60例抗丙型肝炎病毒(HCV)阳性的非肝硬化慢性活动性肝炎患者中(17例未治疗,43例接受单次或重复疗程干扰素治疗),在平均76±18个月的随访期内,评估了HCV感染的行为,包括HCV基因型的类型和数量(采用基因型特异性巢式聚合酶链反应检测)。在未治疗的患者中(2例基因型I、6例基因型II、9例混合感染),9例混合感染患者中有4例在随访结束时选择了基因型II。43例接受治疗的患者中,10例为组织学缓解的长期应答者,6例为短期应答者,22例无应答。后一组患者中有15例接受了另一疗程的干扰素治疗,只有3例有应答。10例应答者中有8例感染单一基因型(4例基因型I、3例基因型II、3例基因型III)。干扰素治疗后,除2例患者外,所有患者的HCV感染均得到清除。第二次干扰素疗程的应答者(1例基因型I、1例基因型II、1例基因型III)仍有病毒血症。在短期应答者中,2/6患者为基因型II,4例为混合感染(3例基因型II±I和1例基因型II±III);除1例患者外,基因型III在后者中变得普遍。在无应答者中,18/24有不止一种基因型,5例基线时为基因型II,1例为基因型I。随访期末,15/18例混合感染患者选择了基因型II(与未治疗患者相比,P<0.01)。(摘要截断于250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验